Research map: Clinical and economic impact on people with relapsing-remitting multiple sclerosis in the United States: a matched-cohort study

Back to the article

Papers in this map

  1. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation · Mary E. Charlson · 1987 · 50679 citations · Cited by this paper
  2. Promising results amid persistent disparities in real-world adherence to multitarget stool DNA testing · 2026 · Related
  3. Rating neurologic impairment in multiple sclerosis · John F. Kurtzke · 1983 · 15108 citations · Cited by this paper
  4. Original Abstracts from the 22nd Annual Meeting of ISMPP · 2026 · Related
  5. Multiple sclerosis · Dejan Jakimovski · 2023 · 598 citations · Cited by this paper
  6. Real-world comparison of androgen receptor pathway ınhibitors versus docetaxel as first-line treatment in metastatic hormone-sensitive prostate cancer · 2026 · Related
  7. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies · Gustavo Luna · 2019 · 527 citations · Cited by this paper
  8. Quantifying US healthcare provider preferences for the treatment of post-transplant cytomegalovirus infection using a discrete choice experiment · 2026 · Related
  9. Clinical Course of Multiple Sclerosis · Sylvia Klineova · 2018 · 409 citations · Cited by this paper
  10. Serum calcium and liver injury in people living with HIV: a longitudinal cohort study in Southeast China · 2026 · Related
  11. Disease‐modifying treatments for multiple sclerosis – a review of approved medications · Øivind Torkildsen · 2015 · 290 citations · Cited by this paper
  12. A novel hypothesis for stroke prediction, introducing CHA 2 DS 2 -VAScF · 2026 · Related
  13. Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis · Stephen L. Hauser · 2021 · 193 citations · Cited by this paper
  14. Seizing the opportune moment: early use of antiplatelet therapy for thrombolysis · 2026 · Related
  15. Gait Abnormalities in Multiple Sclerosis: Pathogenesis, Evaluation, and Advances in Treatment · Michelle H. Cameron · 2011 · 161 citations · Cited by this paper
  16. Tirzepatide compared with semaglutide in obesity disease: a subpopulation analysis applying Japan Society for the Study of Obesity criteria in the global SURMOUNT-5 trial · 2026 · Related
  17. Multiple sclerosis: time for early treatment with high-efficacy drugs · Krzysztof W. Selmaj · 2023 · 90 citations · Cited by this paper
  18. Original Abstracts from the 2026 European Meeting of ISMPP · 2026 · Related
  19. Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years · Stephen L. Hauser · 2022 · 82 citations · Cited by this paper
  20. Adverse effect profile of amphotericin B deoxycholate administered with a standardized infusion protocol in hematologic patients: a prospective study in a resource-limited setting · 2026 · Related
  21. Symptoms and Association with Health Outcomes in Relapsing-Remitting Multiple Sclerosis: Results of a US Patient Survey · Angela Williams · 2014 · 49 citations · Cited by this paper
  22. Burden of relapsing-remitting multiple sclerosis on workers in the US: a cross-sectional analysis of survey data · Jacqueline A. Nicholas · 2019 · 36 citations · Cited by this paper
  23. The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations · Irene Eriksson · 2018 · 25 citations · Cited by this paper
  24. Identifying Patients With Relapsing-Remitting Multiple Sclerosis Using Algorithms Applied to US Integrated Delivery Network Healthcare Data · Hoa Le · 2018 · 16 citations · Cited by this paper
  25. Assessment of economic burden of fatigue in adults with multiple sclerosis: An analysis of US National Health and Wellness Survey data · Hoa H. Le · 2022 · 16 citations · Cited by this paper
  26. Shifting from the treat-to-target to the early highly effective treatment approach in patients with multiple sclerosis – real-world evidence from Germany · Steffeni Papukchieva · 2024 · 16 citations · Cited by this paper
  27. Fatigue and health-related quality of life depend on the disability status and clinical course in RRMS · Henrik Ahvenjärvi · 2023 · 12 citations · Cited by this paper
  28. Creating a Real-World Data, United States Healthcare Claims-Based Adaptation of Kurtzke Functional Systems Scores for Assessing Multiple Sclerosis Severity and Progression · Chi Thi Le Truong · 2021 · 10 citations · Cited by this paper
  29. Comorbidity in multiple sclerosis: Emphasis on patient-reported outcomes · Birutė Diržiuvienė · 2022 · 7 citations · Cited by this paper
  30. Claims-based algorithm to estimate the Expanded Disability Status Scale for multiple sclerosis in a German health insurance fund: a validation study using patient medical records · Erwan Muros‐Le Rouzic · 2023 · 6 citations · Cited by this paper
  31. Understanding the Symptoms and Impacts Experienced by People with Relapsing–Remitting MS: A Qualitative Investigation Using Semi-Structured Interviews · Amy M Barrett · 2024 · 5 citations · Cited by this paper

Source: OpenAlex (CC0)